CMS To Decide On NCD For Aduhelm, Future Similar Drugs In Nine Months

CMS on Monday (July 12) launched a National Coverage Determination analysis to decide whether and under what circumstances Medicare will cover Biogen’s costly Alzheimer’s drug Aduhelm as well as any future monoclonal antibodies that also target amyloids to treat Alzheimer’s disease. The agency says it will propose its decision within six months and make a final determination three months later in 2022. In the meantime, coverage determinations for Biogen’s drug will be made at the local level by Medicare Administrative...